FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293554382> ?p ?o ?g. }

• W4293554382 abstract "Abstract Background Insertion of a central venous access device (CVAD) allows clinicians to easily access the circulation of a patient to administer life-saving interventions. Due to their invasive nature, CVADs are prone to complications such as bacterial biofilm production and colonization, catheter-related bloodstream infection, occlusion, and catheter-related venous thrombosis. A CVAD is among the most common interventions for patients in the intensive care unit (ICU), exposing this vulnerable population to the risk of nosocomial infection and catheter occlusion. The current standard of care involves the use of normal saline as a catheter locking solution for central venous catheters (CVCs) and peripherally inserted central catheter (PICC) lines, and a citrate lock for hemodialysis catheters. Saline offers little prophylactic measures against catheter complications. Four percent of tetrasodium ethylenediaminetetraacetic acid (EDTA) fluid (marketed as KiteLock Sterile Locking Solution™) is non-antibiotic, possesses antimicrobial, anti-biofilm, and anti-coagulant properties, and is approved by Health Canada as a catheter locking solution. As such, it may be a superior CVAD locking solution than the present standard of care lock in the ICU patient population. Methods Our team proposes to fill this knowledge gap by performing a multi-center, cluster-randomized, crossover trial evaluating the impact of 4% tetrasodium EDTA on a primary composite outcome of the incidence rate of central line-associated bloodstream infection (CLABSI), catheter occlusion leading to removal, and use of alteplase to resolve catheter occlusion compared to the standard of care. The study will be performed at five critical care units. Discussion If successful, the results of this study can serve as evidence for a shift of standard of care practices to include EDTA locking fluid in routine CVAD locking procedures. Completion of this study has the potential to improve CVAD standard of care to become safer for patients, as well as provides an opportunity to decrease strain on healthcare budgets related to treating preventable CVAD complications. Success and subsequent implementation of this intervention in the ICU may also be extrapolated to other patient populations with heavy CVAD use including hemodialysis, oncology, parenteral nutrition, and pediatric patient populations. On a global scale, eradicating biofilm produced by antibiotic-resistant bacteria may serve to lessen the threat of “superbugs” and contribute to international initiatives supporting the termination of antibiotic overuse. Trial registration ClinicalTrials.gov NCT04548713, registered on September 9th, 2020." @default.
• W4293554382 created "2022-08-30" @default.
• W4293554382 creator A5009546214 @default.
• W4293554382 creator A5018971642 @default.
• W4293554382 creator A5023506411 @default.
• W4293554382 creator A5060475281 @default.
• W4293554382 creator A5061980278 @default.
• W4293554382 creator A5063360595 @default.
• W4293554382 creator A5064059636 @default.
• W4293554382 creator A5069905750 @default.
• W4293554382 date "2022-08-30" @default.
• W4293554382 modified "2023-10-01" @default.
• W4293554382 title "Control of Line Complications with KiteLock (CLiCK) in the critical care unit: study protocol for a multi-center, cluster-randomized, double-blinded, crossover trial investigating the effect of a novel locking fluid on central line complications in the critical care population" @default.
• W4293554382 cites W1530030940 @default.
• W4293554382 cites W1545669160 @default.
• W4293554382 cites W1555706768 @default.
• W4293554382 cites W1867884843 @default.
• W4293554382 cites W1931146984 @default.
• W4293554382 cites W1990410400 @default.
• W4293554382 cites W2020815942 @default.
• W4293554382 cites W2049397086 @default.
• W4293554382 cites W2061991526 @default.
• W4293554382 cites W2098900075 @default.
• W4293554382 cites W2115102414 @default.
• W4293554382 cites W2128252980 @default.
• W4293554382 cites W2131972531 @default.
• W4293554382 cites W2156036886 @default.
• W4293554382 cites W2163400413 @default.
• W4293554382 cites W2166356134 @default.
• W4293554382 cites W2166642038 @default.
• W4293554382 cites W2325184931 @default.
• W4293554382 cites W2617698351 @default.
• W4293554382 cites W2806145963 @default.
• W4293554382 cites W2885978912 @default.
• W4293554382 cites W2902747809 @default.
• W4293554382 cites W2955411783 @default.
• W4293554382 cites W3008310671 @default.
• W4293554382 cites W3047906951 @default.
• W4293554382 cites W3068089061 @default.
• W4293554382 cites W3112630592 @default.
• W4293554382 cites W3130414203 @default.
• W4293554382 cites W3175947413 @default.
• W4293554382 cites W4206383318 @default.
• W4293554382 cites W49051075 @default.
• W4293554382 doi "https://doi.org/10.1186/s13063-022-06671-5" @default.
• W4293554382 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36042488" @default.
• W4293554382 hasPublicationYear "2022" @default.
• W4293554382 type Work @default.
• W4293554382 citedByCount "3" @default.
• W4293554382 countsByYear W42935543822023 @default.
• W4293554382 crossrefType "journal-article" @default.
• W4293554382 hasAuthorship W4293554382A5009546214 @default.
• W4293554382 hasAuthorship W4293554382A5018971642 @default.
• W4293554382 hasAuthorship W4293554382A5023506411 @default.
• W4293554382 hasAuthorship W4293554382A5060475281 @default.
• W4293554382 hasAuthorship W4293554382A5061980278 @default.
• W4293554382 hasAuthorship W4293554382A5063360595 @default.
• W4293554382 hasAuthorship W4293554382A5064059636 @default.
• W4293554382 hasAuthorship W4293554382A5069905750 @default.
• W4293554382 hasBestOaLocation W42935543821 @default.
• W4293554382 hasConcept C141071460 @default.
• W4293554382 hasConcept C142724271 @default.
• W4293554382 hasConcept C168563851 @default.
• W4293554382 hasConcept C177713679 @default.
• W4293554382 hasConcept C194828623 @default.
• W4293554382 hasConcept C204787440 @default.
• W4293554382 hasConcept C27081682 @default.
• W4293554382 hasConcept C2776268601 @default.
• W4293554382 hasConcept C2776376669 @default.
• W4293554382 hasConcept C2778446481 @default.
• W4293554382 hasConcept C2779443120 @default.
• W4293554382 hasConcept C2781267111 @default.
• W4293554382 hasConcept C2908647359 @default.
• W4293554382 hasConcept C2987404301 @default.
• W4293554382 hasConcept C42219234 @default.
• W4293554382 hasConcept C501593827 @default.
• W4293554382 hasConcept C71924100 @default.
• W4293554382 hasConcept C78221805 @default.
• W4293554382 hasConcept C86803240 @default.
• W4293554382 hasConcept C87813604 @default.
• W4293554382 hasConcept C89423630 @default.
• W4293554382 hasConcept C99454951 @default.
• W4293554382 hasConceptScore W4293554382C141071460 @default.
• W4293554382 hasConceptScore W4293554382C142724271 @default.
• W4293554382 hasConceptScore W4293554382C168563851 @default.
• W4293554382 hasConceptScore W4293554382C177713679 @default.
• W4293554382 hasConceptScore W4293554382C194828623 @default.
• W4293554382 hasConceptScore W4293554382C204787440 @default.
• W4293554382 hasConceptScore W4293554382C27081682 @default.
• W4293554382 hasConceptScore W4293554382C2776268601 @default.
• W4293554382 hasConceptScore W4293554382C2776376669 @default.
• W4293554382 hasConceptScore W4293554382C2778446481 @default.
• W4293554382 hasConceptScore W4293554382C2779443120 @default.
• W4293554382 hasConceptScore W4293554382C2781267111 @default.
• W4293554382 hasConceptScore W4293554382C2908647359 @default.
• W4293554382 hasConceptScore W4293554382C2987404301 @default.
• W4293554382 hasConceptScore W4293554382C42219234 @default.
• W4293554382 hasConceptScore W4293554382C501593827 @default.
• W4293554382 hasConceptScore W4293554382C71924100 @default.
• W4293554382 hasConceptScore W4293554382C78221805 @default.

• next